Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Prospective Trial Utilizing Short Course Androgen Deprivation Therapy In Conjunction With Ultra-Hypofractionated SBRT For High Risk Nccn Prostate Cancer With Lower Risk Artera Scores

NCT07801664 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT07801664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07801664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Prospective Trial Utilizing Short Course Androgen Deprivation Therapy In Conjunction With Ultra-Hypofractionated SBRT For High Risk Nccn Prostate Cancer With Lower Risk Artera Scores
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Recruiting
Start date
August 6, 2026
Completion date
August 1, 2029
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer